Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY ASIMTUFII vs BILTRICIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.
Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.
Schizophrenia,Maintenance monotherapy treatment of bipolar I disorder
Treatment of schistosomiasis (all species),Treatment of clonorchiasis sinensis (liver fluke),Treatment of opisthorchiasis (liver fluke),Off-label: Treatment of neurocysticercosis (in combination with corticosteroids),Off-label: Treatment of other trematode infections (e.g., fasciolopsiasis, intestinal flukes),Off-label: Treatment of cestode infections (e.g., diphyllobothriasis, taeniasis)
Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.
60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.
Terminal elimination half-life: 29-40 days (aripiprazole) and 48-63 days (dehydraripiprazole), allowing monthly dosing.
Terminal elimination half-life is approximately 0.8-1.5 hours for praziquantel; clinical significance: short half-life necessitates multiple dosing for sustained antiparasitic effect.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole is formed primarily by CYP3A4 and CYP2D6; exhibits significant interindividual variability due to CYP2D6 polymorphism.
Extensively metabolized by the liver, primarily by cytochrome P450 enzymes (CYP3A4), to inactive hydroxylated metabolites.
Renal (approximately 25% unchanged and 55% as metabolites), fecal (approximately 20%).
Renal excretion accounts for approximately 80-90% of elimination, primarily as metabolites; biliary/fecal excretion is minor (<10%).
>99% bound to serum albumin.
Approximately 80-85% bound to serum albumin.
4.9 L/kg, indicating extensive extravascular distribution.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution.
Intramuscular: 100% (as a depot suspension).
Oral bioavailability is approximately 80% due to extensive first-pass metabolism; higher with food.
No dosage adjustment required for patients with renal impairment (Cr Cl ≥15 m L/min). Insufficient data for patients with end-stage renal disease (Cr Cl <15 m L/min).
No dosage adjustment required for any degree of renal impairment.
No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh class A or B). Use with caution in severe hepatic impairment (Child-Pugh class C) as experience is limited.
No specific Child-Pugh based adjustments; contraindicated in hepatocellular carcinoma or history of hepatic encephalopathy; use caution in severe liver disease.
Not approved for use in pediatric patients. Safety and efficacy have not been established.
4 years and older: 60 mg/kg/day in 3 divided doses for 1 day; maximum single dose 2 g.
Use with caution due to increased sensitivity to orthostatic hypotension and sedative effects. Consider lower starting doses (300 mg orally equivalent) but no specific dose adjustment for the injectable form is recommended.
No specific adjustments; use standard adult dosing with monitoring for adverse effects.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Asimtufii is not approved for the treatment of patients with dementia-related psychosis.
None.
Increased mortality in elderly patients with dementia-related psychosis; cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly patients with dementia-related psychosis; neuroleptic malignant syndrome (NMS); tardive dyskinesia; metabolic changes (hyperglycemia/diabetes mellitus, dyslipidemia, weight gain); pathological gambling and other compulsive behaviors; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; potential for additive effects with alcohol or CNS depressants; injection site reactions; risk of extrapyramidal symptoms; suicidal thoughts/behaviors.
Avoid grapefruit juice during treatment due to increased praziquantel exposure.,May cause transient neurologic symptoms in patients with cerebral schistosomiasis or neurocysticercosis due to inflammatory reaction around dying parasites.,Use with caution in patients with hepatic impairment (Child-Pugh class B or C) as metabolism may be reduced.,May exacerbate cysticercosis if used without corticosteroids in neurocysticercosis.,Potential for cardiac arrhythmias in patients with ventricular arrhythmias or electrolyte disturbances (rare).
Known hypersensitivity to aripiprazole or any component of the formulation; concurrent use of strong CYP3A4 inducers (e.g., carbamazepine, rifampin)
Hypersensitivity to praziquantel or any component of the formulation,Ocular cysticercosis (due to risk of irreversible ocular damage from inflammatory response),Concurrent use with rifampin (significantly reduces praziquantel plasma concentrations),Children under 1 year of age (safety not established)
Avoid grapefruit juice and grapefruit products as they may increase aripiprazole levels. Alcohol should be limited or avoided due to additive CNS depression and increased risk of sedation.
Take with food to enhance bioavailability. Avoid grapefruit juice as it may increase drug levels. Alcohol may worsen CNS side effects and is not recommended.
Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Advise use only if benefit outweighs risk.
Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major malformations reported. Avoid in first trimester unless essential; use in second/third trimester if benefit outweighs risk.
Excreted in human milk; limited data. M/P ratio not established. Decision to discontinue nursing or drug based on importance of drug to mother. Use caution.
Praziquantel is excreted into breast milk in small amounts; M/P ratio not established. After a single dose, milk levels low; consider pumping and discarding milk for 24-48 hours post-dose. Use with caution in nursing mothers.
No recommended dose adjustments in pregnancy; consider pharmacokinetic changes (e.g., increased clearance) may require titration, but evidence lacking.
No dose adjustment required for pregnancy; standard dosing (20 mg/kg three times daily for 1 day) unless hepatic impairment present. Pharmacokinetics in pregnancy not significantly altered; unchanged recommendations.
ABILIFY ASIMTUFII (aripiprazole) is a long-acting injectable suspension for intramuscular use. Administer only by a healthcare professional. Observe patient for 2 hours post-injection due to risk of post-injection delirium/sedation syndrome. Requires 3 consecutive daily doses of oral aripiprazole (10-20 mg) before initiation to confirm tolerability. Dosing: 441 mg IM monthly (equates to 400 mg aripiprazole). Do not substitute with other aripiprazole formulations on a mg-per-mg basis. Contraindicated in patients with known hypersensitivity to aripiprazole.
Administer with food to increase absorption and reduce GI side effects. Use with caution in hepatic impairment; dose adjustment may be necessary. Monitor for neuropsychiatric effects (e.g., dizziness, headache) especially in patients with CNS involvement of schistosomiasis. Avoid in patients with ocular cysticercosis due to risk of intraocular inflammation; treat ocular lesions first with corticosteroids.
This medication is given as an injection once a month by your healthcare provider.,Do not try to inject yourself; it must be given by a healthcare professional.,After each injection, you will need to stay at the doctor's office or clinic for at least 2 hours to be monitored for any serious side effects.,You will need to take oral aripiprazole for 3 days before your first injection to see if you can tolerate the medication.,Common side effects include headache, insomnia, nausea, and injection site pain.,Seek emergency care if you have allergic reaction (hives, difficulty breathing, swelling), uncontrolled muscle movements, or thoughts of suicide.,Avoid alcohol and grapefruit juice while on this medication.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment without consulting your doctor.
Take this medication with a meal to improve absorption and reduce stomach upset.,Do not chew or crush the tablets; swallow them whole.,Complete the full course of treatment even if you feel better.,You may experience dizziness, drowsiness, or headache; avoid driving or operating heavy machinery until you know how the drug affects you.,Inform your doctor if you have liver disease or are taking other medications.,Contact your doctor if you experience severe headache, seizures, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY ASIMTUFII vs BILTRICIDE, answered by our medical review team.
ABILIFY ASIMTUFII is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.. BILTRICIDE is a Anthelmintic that works by Praziquantel increases the permeability of cell membranes to calcium ions in susceptible schistosomes and other trematodes, causing sustained contraction and paralysis of the worm musculature, leading to detachment from blood vessel walls and eventual death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY ASIMTUFII and BILTRICIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY ASIMTUFII is: Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.. The standard adult dose of BILTRICIDE is: 60 mg/kg/day orally in 3 divided doses (20 mg/kg/dose) for 1 day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY ASIMTUFII and BILTRICIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY ASIMTUFII is classified as Category C. Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Adv. BILTRICIDE is classified as Category C. Praziquantel (Biltricide) is FDA Pregnancy Category B. Animal studies show no teratogenic effects but embryotoxicity at high doses. Human data limited; no increased risk of major m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.